最近的研究表明，一特定群体的带核细胞，在外显红细胞标志物（小鼠中的TER119和人类中的CD235a）的基础上表现出具有抑制免疫系统和促进肿瘤生长的能力。这些细胞被称为CD45+红细胞前体细胞（EPCs）。根据我们的研究，似乎这些CD45+ EPCs的子集起源于B淋巴细胞。在缺氧条件下，小鼠B淋巴瘤细胞能够转化为类似红细胞祖细胞的细胞，显示出CD45+TER119+细胞的表型特征，包括对CD8 T细胞的免疫抑制作用。此外，非肿瘤性B细胞在小鼠中的贫血或肿瘤条件下也具有相似的分化能力，并对免疫抑制产生相同效应。类似的B细胞存在于新生小鼠中，这提供了新生儿中可能起源于免疫抑制性红细胞的潜在解释。此外，CD19+CD235a+双阳性细胞可在患有慢性淋巴细胞白血病的患者的外周血中被鉴定出。这些发现表明，一些CD45+ EPCs是由特定种群的CD19+ B淋巴细胞在应对环境压力下转分化而来，突显了B淋巴细胞的可塑性。我们预计，在治疗上，目标锁定特定的B细胞群体而非红细胞应该能够恢复适应性免疫力并延缓癌症进展。 © 2023 Yang, Wang, Wu, Wang, Xu, Liu, Wang and Yu.

Recent studies have demonstrated that a particular group of nucleated cells that exhibit erythroid markers (TER119 in mice and CD235a in humans) possess the ability to suppress the immune system and promote tumor growth. These cells are known as CD45+ erythroid progenitor cells (EPCs). According to our study, it appears that a subset of these CD45+ EPCs originate from B lymphocytes. Under conditions of hypoxia, mouse B lymphoma cells are capable of converting to erythroblast-like cells, which display phenotypes of CD45+TER119+ cells, including immunosuppressive effects on CD8 T cells. Furthermore, non-neoplastic B cells have similar differentiation abilities and exert the same immunosuppressive effect under anemia or tumor conditions in mice. Similar B cells exist in neonatal mice, which provides an explanation for the potential origin of immunosuppressive erythroid cells in newborns. Additionally, CD19+CD235a+ double-positive cells can be identified in the peripheral blood of patients with chronic lymphocytic leukemia. These findings indicate that some CD45+ EPCs are transdifferentiated from a selective population of CD19+ B lymphocytes in response to environmental stresses, highlighting the plasticity of B lymphocytes. We anticipate a potential therapeutic implication, in that targeting a specific set of B cells instead of erythroid cells should be expected to restore adaptive immunity and delay cancer progression.Copyright © 2023 Yang, Wang, Wu, Wang, Xu, Liu, Wang and Yu.